Chun Zhang Yang, Ph.D.
Dr. Chun Zhang Yang is a principal investigator in the Neuro-Oncology Branch (NOB), which is a collaboration between the National Cancer Institute (NCI) and the National Institute of Neurological Disorders and Stroke (NINDS). Dr. Yang is experienced in multi-discipline medical research, with focuses on signaling pathways, functional genetics, and metabolomics in brain tumors. He has been leading and performing research endeavors in the fields of basic, translational, and clinical research projects, aiming for a more efficient translation from laboratory findings to pre-clinical testing. Dr. Yang’s group focuses on exploring the signaling mechanisms that are related to tumor aggressiveness and malignancy and seeking novel therapeutic approaches by targeting these pathways.
1) brain tumor, 2) cancer biology, 3) cancer metabolism, 4) oncometabolites, 5) protein post-translational modifications, 6) genetic engineering
Glioma, a devastating disease affecting thousands of lives in the United States, is the most common form of central nervous system cancer, with an estimated 20,000 newly diagnosed cases each year. It causes multiple neurological symptoms ranging from headache, nausea to drowsiness, dysphagia, epilepsy, and mortality. Gliomas are difficult to treat and exhibit unfavorable disease outcomes. For example, patients with WHO Grade IV glioblastoma (GBM), the median survival is < 18 months, with a 5% five-year survival rate. While the prognosis for patients with lower grade gliomas is better, these cancers remain incurable. Although advances in glioma research have revealed the genetic, epigenetic, and metabolic signatures of different glioma molecular subtypes, the standards of care in glioma management remain limited and nonselective. There are many caveats to the translation of knowledge on glioma molecular subtypes into effective therapeutics. Therefore, there is an urgent need to improve the present therapeutic regimen based on molecular signatures to achieve better selectivity and efficacy with prolonged patient survival.
The goal of our research program is to identify the therapeutic vulnerabilities in the major glioma molecular subtypes. In particular, we focused on glioma with isocitrate dehydrogenase (IDH) mutations, which is the most prevalent genetic abnormality in over 80% of patients with WHO II/III glioma. Several findings suggested that mutations in IDH result in distinctive changes in tumor biology, such as overproduction of oncometabolite 2-hydroxyglutarate (2-HG), development of a hypermethylation phenotype, and redox imbalance. Based on the knowledge of IDH1-mutated glioma, we hypothesize that the distinctive pattern of cancer biology, metabolism, and therapeutic resistance in IDH-mutated glioma offer novel therapeutic targets, suggesting that the present therapeutic regimen could be optimized/enhanced by targeted therapy. Based on this hypothesis, we began our investigation by comparing the transcriptomic and metabolomic profiles between IDH1 wild type and mutated cells. In addition, we have been developing patient-derived cells, intracranial xenograft models, and genetically engineered mouse models for IDH1-mutated glioma, which serve as useful tools to validate cancer-susceptible and -resistant genes. Our findings demonstrate that several protective mechanisms, including macropinocytosis-derived nutrient uptake, nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-governed detoxification, and DNA repair pathways, play central roles to prevent metabolic stress and apoptotic changes in IDH1-mutated cells. Based on our preliminary findings, we identified novel therapeutic targets and validated them using in vitro assays and preclinical animal models. Our findings suggest novel therapeutic strategies that can result in optimized efficacy and selectivity for IDH1-mutated cancer. Our research on IDH1-mutated glioma cells and mouse models will introduce complementary techniques and impart knowledge that can be extended to future glioma translational research.
We believe that our contribution will be of great significance because our research introduces conceptual advances in glioma biology and therapeutics. In addition, the portfolio of this research platform, including IDH1-mutated cells and genetically engineered mouse models, will serve as foundational resources for the emerging field of cancer metabolism. We expect that our immediate results, as well as subsequent work, will improve the quality of life and medical outcomes for patients with glioma.
Selected Key Publications
- Journal of the National Cancer Institute. Epub ahead of print: 2019. [ Journal Article ]
Targeting NAD+/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma.Clinical Cancer Research. 24: 3423-3432, 2018. [ Journal Article ]
- Cancer Research. 77(7): 1709-1718, 2017. [ Journal Article ]
β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas.Proc Natl Acad Sci U S A. 109(18): 6963-6968, 2012. [ Journal Article ]
- N Engl J Med. 367(10): 922-930, 2012. [ Journal Article ]
|Sue Han Ph.D.||Postdoctoral Fellow (Visiting)|
|Yang Liu Ph.D.||Postdoctoral Fellow (Visiting)|
|Mingyu Qian||Special Volunteer|
Dr. Yanxin Lu (Postdoc fellow 2016-2018) conducted an oral presentation regarding her laboratory work in NOB in AACR Annual Meeting 2017.
Dr. Yang Liu (Postdoc fellow 2016- ) won the best poster award in 2018 Annual Symposium for the Society for Neuro-Oncology.
Our publication won "The Best of the AACR Journals" with a most-cited article in Cancer Research. Image taken during AACR Annual Meeting 2019.
On May 22nd, 2018, Dr. Yanxin Lu (Postdoc fellow 2016-2018) gave birth of a baby boy Ziyuan Yue (Jefferson).